These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 36610058)

  • 1. Results from a test-and-treat study for influenza among residents of homeless shelters in King County, WA: A stepped-wedge cluster-randomized trial.
    Rogers JH; Casto AM; Nwanne G; Link AC; Martinez MA; Nackviseth C; Wolf CR; Hughes JP; Englund JA; Sugg N; Uyeki TM; Han PD; Pfau B; Shendure J; Chu HY
    Influenza Other Respir Viruses; 2023 Jan; 17(1):e13092. PubMed ID: 36610058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Point-of-care molecular testing and antiviral treatment of influenza in residents of homeless shelters in Seattle, WA: study protocol for a stepped-wedge cluster-randomized controlled trial.
    Newman KL; Rogers JH; McCulloch D; Wilcox N; Englund JA; Boeckh M; Uyeki TM; Jackson ML; Starita L; Hughes JP; Chu HY;
    Trials; 2020 Nov; 21(1):956. PubMed ID: 33228787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.
    Fry AM; Goswami D; Nahar K; Sharmin AT; Rahman M; Gubareva L; Azim T; Bresee J; Luby SP; Brooks WA
    Lancet Infect Dis; 2014 Feb; 14(2):109-18. PubMed ID: 24268590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virological and clinical outcomes in outpatients treated with baloxavir or oseltamivir: A Japanese multicenter study in the 2019-2020 influenza season.
    Chong Y; Kawai N; Tani N; Bando T; Takasaki Y; Shindo S; Ikematsu H
    Antiviral Res; 2021 Aug; 192():105092. PubMed ID: 34052230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial.
    Ison MG; Portsmouth S; Yoshida Y; Shishido T; Mitchener M; Tsuchiya K; Uehara T; Hayden FG
    Lancet Infect Dis; 2020 Oct; 20(10):1204-1214. PubMed ID: 32526195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors promoting the prolonged shedding of the pandemic (H1N1) 2009 influenza virus in patients treated with oseltamivir for 5 days.
    Ryoo SM; Kim WY; Sohn CH; Seo DW; Oh BJ; Lee JH; Lee YS; Lim KS
    Influenza Other Respir Viruses; 2013 Sep; 7(5):833-7. PubMed ID: 23279949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China.
    Cao B; Li XW; Mao Y; Wang J; Lu HZ; Chen YS; Liang ZA; Liang L; Zhang SJ; Zhang B; Gu L; Lu LH; Wang DY; Wang C;
    N Engl J Med; 2009 Dec; 361(26):2507-17. PubMed ID: 20007555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical effectiveness of baloxavir marboxil against influenza in three seasons.
    Kakuya F; Okubo H; Fujiyasu H; Kurisawa MJ; Kinebuchi T
    Pediatr Int; 2022 Jan; 64(1):e15169. PubMed ID: 35790049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a rapid molecular algorithm for detection of pandemic influenza A (H1N1) 2009 virus and screening for a key oseltamivir resistance (H275Y) substitution in neuraminidase.
    van der Vries E; Jonges M; Herfst S; Maaskant J; Van der Linden A; Guldemeester J; Aron GI; Bestebroer TM; Koopmans M; Meijer A; Fouchier RA; Osterhaus AD; Boucher CA; Schutten M
    J Clin Virol; 2010 Jan; 47(1):34-7. PubMed ID: 19857993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of oseltamivir and zanamivir resistance in influenza A(H1N1)pdm09 virus, Denmark, 2014.
    Trebbien R; Pedersen SS; Vorborg K; Franck KT; Fischer TK
    Euro Surveill; 2017 Jan; 22(3):. PubMed ID: 28128091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duration of fever and symptoms in influenza-infected children treated with baloxavir marboxil during the 2019-2020 season in Japan and detection of influenza virus with the PA E23K substitution.
    Wagatsuma K; Saito R; Chon I; Phyu WW; Fujio K; Kawashima T; Sato I; Saito T; Minato M; Kodo N; Suzuki E; Ono Y; Masaki H; Shirahige Y; Kitano A; Hamabata H; Yuyang S; Jiaming L; Watanabe H
    Antiviral Res; 2022 May; 201():105310. PubMed ID: 35358601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of four COVID-19 screening strategies to facilitate early case identification within the homeless shelter population: A structured summary of a study protocol for a randomised controlled trial.
    O'Shea T; Mbuagbaw L; Mokashi V; Bulir D; Gilchrist J; Smieja N; Chong S; Marttala S; Vera V; Cvetkovic A; Smieja M
    Trials; 2020 Nov; 21(1):941. PubMed ID: 33225995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of oseltamivir resistance in Sydney, during the Newcastle outbreak of community transmitted oseltamivir-resistant influenza A(H1N1)pdm09 virus, Australia, June to August 2011.
    Wang B; Taylor J; Ratnamohan M; McPhie K; Kesson A; Dixit R; Booy R; Hurt A; Saksena N; Dwyer DE
    Euro Surveill; 2012 Jul; 17(27):. PubMed ID: 22790606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and virological outcomes with baloxavir compared with oseltamivir in pediatric patients aged 6 to < 12 years with influenza: an open-label, randomized, active-controlled trial protocol.
    Ishiguro N; Morioka I; Nakano T; Furukawa M; Tanaka S; Kinoshita M; Manabe A
    BMC Infect Dis; 2021 Aug; 21(1):777. PubMed ID: 34372769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Aug; 58(32):893-6. PubMed ID: 19696719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial.
    Wang C; Cao B; Liu QQ; Zou ZQ; Liang ZA; Gu L; Dong JP; Liang LR; Li XW; Hu K; He XS; Sun YH; An Y; Yang T; Cao ZX; Guo YM; Wen XM; Wang YG; Liu YL; Jiang LD
    Ann Intern Med; 2011 Aug; 155(4):217-25. PubMed ID: 21844547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subtype-specific Clinical Presentation, Medical Treatment and Family Impact of Influenza in Children 1-5 Years of Age Treated in Outpatient Practices in Germany During Three Postpandemic Years, 2013-2015.
    Streng A; Prifert C; Weissbrich B; Sauerbrei A; Schmidt-Ott R; Liese JG
    Pediatr Infect Dis J; 2018 Sep; 37(9):861-867. PubMed ID: 29406467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral shedding and susceptibility to oseltamivir in hospitalized immunocompromised patients with influenza in the Influenza Resistance Information Study (IRIS).
    Fraaij PL; Schutten M; Javouhey E; Burleigh L; Outlaw R; Kumar D; Boucher CA
    Antivir Ther; 2015; 20(6):633-42. PubMed ID: 25849228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children.
    Stephenson I; Democratis J; Lackenby A; McNally T; Smith J; Pareek M; Ellis J; Bermingham A; Nicholson K; Zambon M
    Clin Infect Dis; 2009 Feb; 48(4):389-96. PubMed ID: 19133796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic characterisation of influenza A(H1N1)pdm09 viruses circulating in Assam, Northeast India during 2009-2015.
    Biswas D; Dutta M; Sarmah K; Yadav K; Buragohain M; Sarma K; Borkakoty B
    Indian J Med Microbiol; 2019; 37(1):42-49. PubMed ID: 31424009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.